This page uses content from Wikipedia and is licensed under CC BY-SA.


Skeletal formula
Space-filling model of zonampanel
Clinical data
ATC code
  • None
CAS Number
PubChem CID
CompTox Dashboard (EPA)
Chemical and physical data
Molar mass331.241 g/mol g·mol−1
3D model (JSmol)

Zonampanel (INN, code name YM872) is a quinoxalinedione derivative drug and competitive antagonist of the AMPA receptor which was being investigated by Yamanouchi/Astellas Pharma as a neuroprotective drug for the treatment of ischemic stroke but never completed clinical trials.[1][2][3][4] In clinical trials, zonampanel produced severe side effects including hallucinations, agitation, and catatonia in patients, resulting in early termination of the trials.[5]


  1. ^ Kewal K. Jain (14 February 2011). The Handbook of Neuroprotection. Springer Science & Business Media. pp. 154–. ISBN 978-1-61779-049-2.
  2. ^ Arunabha Ray, Kavita Gulati (1 January 2007). Current Trends in Pharmacology. I. K. International Pvt Ltd. pp. 321–. ISBN 978-81-88237-77-7.
  3. ^ Stephen Waxman (27 May 2005). Multiple Sclerosis As A Neuronal Disease. Academic Press. pp. 245–. ISBN 978-0-08-048941-4.
  4. ^ Santokh Gill; Olga Pulido (31 January 2007). Glutamate Receptors in Peripheral Tissue: Excitatory Transmission Outside the CNS. Springer Science & Business Media. pp. 37–. ISBN 978-0-306-48644-9.
  5. ^ Akhlaq A. Farooqui (2 September 2010). Neurochemical Aspects of Neurotraumatic and Neurodegenerative Diseases. Springer Science & Business Media. pp. 73–. ISBN 978-1-4419-6652-0.